Absci Corp (ABSI)
4.53
+0.15
(+3.42%)
USD |
NASDAQ |
Jun 10, 16:00
4.53
0.00 (0.00%)
After-Hours: 20:00
Absci Cash from Financing (TTM): 77.80M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 77.80M |
December 31, 2023 | -4.483M |
September 30, 2023 | -1.855M |
June 30, 2023 | -1.852M |
March 31, 2023 | 5.191M |
December 31, 2022 | 5.237M |
September 30, 2022 | 2.548M |
Date | Value |
---|---|
June 30, 2022 | 211.86M |
March 31, 2022 | 205.56M |
December 31, 2021 | 336.19M |
September 30, 2021 | 401.88M |
June 30, 2021 | 193.18M |
March 31, 2021 | 199.98M |
December 31, 2020 | 70.97M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-4.483M
Minimum
Dec 2023
401.88M
Maximum
Sep 2021
121.59M
Average
74.39M
Median
Cash from Financing (TTM) Benchmarks
Eli Lilly and Co | 2.772B |
CytomX Therapeutics Inc | 30.40M |
Bristol-Myers Squibb Co | 8.278B |
Recursion Pharmaceuticals Inc | 152.11M |
NovaBay Pharmaceuticals Inc | 1.313M |